NPS Pharmaceuticals Price Target Raised to $42.00 at Canaccord Genuity (NPSP)
Research analysts at Canaccord Genuity increased their price objective on shares of NPS Pharmaceuticals (NASDAQ:NPSP) from $35.00 to $42.00 in a report released on Monday, American Banking News reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price suggests a potential upside of 29.67% from the company’s current price.
NPS Pharmaceuticals (NASDAQ:NPSP) traded down 0.80% during mid-day trading on Monday, hitting $32.13. The stock had a trading volume of 187,524 shares. NPS Pharmaceuticals has a 1-year low of $7.35 and a 1-year high of $35.72. The stock has a 50-day moving average of $26.17 and a 200-day moving average of $24.67. The company’s market cap is $3.281 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.01. The company had revenue of $39.20 million for the quarter, compared to the consensus estimate of $38.40 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. Analysts expect that NPS Pharmaceuticals will post $-0.21 EPS for the current fiscal year.
In other NPS Pharmaceuticals news, CFO Luke Beshar sold 37,874 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $30.02, for a total value of $1,136,977.48. Following the completion of the transaction, the chief financial officer now directly owns 59,180 shares of the company’s stock, valued at approximately $1,776,584. The sale was disclosed in a filing with the SEC, which is available at this link.
A number of other analysts have also recently weighed in on NPSP. Analysts at Jefferies Group raised their price target on shares of NPS Pharmaceuticals from $21.00 to $28.00 in a research note to investors on Thursday, November 7th. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of NPS Pharmaceuticals in a research note to investors on Wednesday, November 6th. They now have a $47.00 price target on the stock. Finally, analysts at Brean Capital upgraded shares of NPS Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Wednesday, November 6th. They now have a $36.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $37.35.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.